# Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial

*PRI Rank #3 · Topics and Trends in Most Cited Immunotherapy and Immune Responses Papers, Class of 2026*

*Canonical URL: https://pri.pepkio.com/top-papers/immunotherapy-and-immune-responses/2026/rank-3*

| Field | Value |
| --- | --- |
| Rank | #3 |
| 18m citations | 236 |
| Journal | Nature Medicine |
| Year | 2024 |
| DOI | 10.1038/s41591-023-02785-8 |
| Corresponding authors | Katayoun Rezvani |
| Institution | The University of Texas MD Anderson Cancer Center, United States |

**Ranking page:** [Topics and Trends in Most Cited Immunotherapy and Immune Responses Papers, Class of 2026](https://pri.pepkio.com/top-papers/immunotherapy-and-immune-responses/2026)

**Paper link:** [10.1038/s41591-023-02785-8](https://doi.org/10.1038/s41591-023-02785-8)

## Topics

CAR-NK cells · CD19 CAR T-cell therapy · cord blood-derived NK cells · IL-15 · allogeneic CAR T cells · CD19+ B cell malignancies · phase 1/2 trial · Objective response rate (ORR) · progression-free survival · CAR-NK cell persistence · cytokine release syndrome · graft-versus-host disease · cord blood unit selection · nucleated red blood cell count · collection-to-cryopreservation time · effector-related gene signature · hypoxia stress response · cellular stress programs · mouse xenograft models · donor selection criteria

## Cite this ranking

```
Pepkio Research Index (PRI). Topics and Trends in Most Cited Immunotherapy and Immune Responses Papers, Class of 2026. https://pri.pepkio.com/top-papers/immunotherapy-and-immune-responses/2026. Accessed 2026-07-21.

Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459
```